These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23649869)

  • 61. Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase.
    Sonmez M; Ovali E; Omay SB
    J Clin Pharm Ther; 2008 Feb; 33(1):91-2. PubMed ID: 18211624
    [No Abstract]   [Full Text] [Related]  

  • 62. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
    Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
    Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
    Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
    Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
    Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
    Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.
    Breccia M; Alimena G
    Leuk Res; 2010 Feb; 34(2):129-34. PubMed ID: 19783301
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
    Racil Z; Razga F; Drapalova J; Buresova L; Zackova D; Palackova M; Semerad L; Malaskova L; Haluzik M; Mayer J
    Haematologica; 2013 Oct; 98(10):e124-6. PubMed ID: 23716549
    [No Abstract]   [Full Text] [Related]  

  • 68. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
    Gugliotta G; Castagnetti F; Breccia M; Levato L; D'Adda M; Stagno F; Tiribelli M; Salvucci M; Fava C; Martino B; Cedrone M; Bocchia M; Trabacchi E; Cavazzini F; Usala E; Russo Rossi A; Bochicchio MT; Soverini S; Alimena G; Cavo M; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G;
    Haematologica; 2015 Sep; 100(9):1146-50. PubMed ID: 26113419
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nilotinib.
    Ostendorf BN; le Coutre P; Kim TD; Quintás-Cardama A
    Recent Results Cancer Res; 2014; 201():67-80. PubMed ID: 24756785
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
    La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A
    Haematologica; 2008 May; 93(5):765-9. PubMed ID: 18367481
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
    Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
    J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
    Kantarjian H; Giles F; Wunderle L; Bhalla K; O'Brien S; Wassmann B; Tanaka C; Manley P; Rae P; Mietlowski W; Bochinski K; Hochhaus A; Griffin JD; Hoelzer D; Albitar M; Dugan M; Cortes J; Alland L; Ottmann OG
    N Engl J Med; 2006 Jun; 354(24):2542-51. PubMed ID: 16775235
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
    Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
    Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Symptomatic Acute Pancreatitis Induced by Nilotinib: A Report of Two Cases.
    Yamada T; Nannya Y; Shimizu M; Seishima M; Tsurumi H
    Intern Med; 2016; 55(23):3495-3497. PubMed ID: 27904116
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
    Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
    Takahashi N; Nishiwaki K; Nakaseko C; Aotsuka N; Sano K; Ohwada C; Kuroki J; Kimura H; Tokuhira M; Mitani K; Fujikawa K; Iwase O; Ohishi K; Kimura F; Fukuda T; Tanosaki S; Takahashi S; Kameoka Y; Nishikawa H; Wakita H;
    Haematologica; 2018 Nov; 103(11):1835-1842. PubMed ID: 29976734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.